Longevity & Healthy Ageing

Purpose

Scope

Requirements

• Lifespan, Healthspan, Disease Risk, Functional Capacity, Biological Age and Biomarker Change are distinct outcomes and must not be equated without sufficient basis.
• A better marker is not automatically a better outcome. Improvement in a biomarker or surrogate measure does not automatically establish better function, less disease, longer healthspan or extended lifespan.
• A change in a biological-age marker is not automatically evidence of slowed biological ageing or extended human lifespan.
• Professionals must distinguish direct outcomes meaningful to people from biomarkers or surrogate endpoints. Depending on the claim, relevant direct outcomes may include how people feel, function or survive (feel · function · survive).
• Where practical and relevant to the claim, longevity evaluation should not rely exclusively on molecular or algorithmic markers when meaningful functional or clinical outcomes are available.
• A biomarker is not automatically a validated surrogate endpoint. Surrogate validity is context-of-use specific; H-02 Biomarkers & Laboratory Data applies accordingly.
• Even a validated surrogate endpoint in one Context of Use does not automatically validate a longevity claim in another context, population or outcome.
• Biological-age or ageing-clock outputs must be interpreted in the context of Model, Version, Assay, Platform, Processing Pipeline, Population, measured data, validation and intended use case. Biological age is model-dependent, not a single universally measured biological quantity. Proprietary score ≠ validated clinical interpretation.
• Different biological-age clocks or scores must not be treated as interchangeable merely because they output a result in “years” or a similar ageing metric.
• Age prediction or risk prediction is not the same as a validated measurement of ageing rate. Prediction of age or risk ≠ validated measurement of ageing rate.
• Age estimate and Pace of Ageing are distinct constructs. A change in an age-estimate score must not be interpreted as a change in ageing rate without specific validation.
• A change in an ageing score may be influenced by measurement variation, model changes, regression to the mean, changed input data or genuine biological change and must not be causally attributed to an intervention without sufficient basis.
• A single biological-age measurement cannot establish an individual ageing trajectory. Repeated measurements are meaningfully comparable only where model, version, assay, platform, processing pipeline and relevant measurement conditions are sufficiently consistent.
• Chronological age and biological ageing processes are not the same; however, a calculated “biological age” is a model-generated estimate, not a second independently observable birth age or a standalone prognosis of individual lifespan.
• Technical precision does not establish biological or clinical validity. A technically reproducible score may still have limited biological or clinical interpretability.
• Longevity claims must comply with H-01 Health Information & Claims and U-03 Evidence & Scientific Communication. Claims such as “reverses ageing,” “slows ageing,” “extends lifespan,” or similarly strong statements require evidence that supports that specific claim and relevant outcome.
• The claim “extends human lifespan” requires evidence directly relevant to that human-lifespan outcome; biomarker, animal, mechanistic or short-term physiological data are not sufficient on their own.
• “Age reversal” is not a sufficiently precise claim without a defined endpoint. The statement must specify whether it refers to a biomarker, model score, functional outcome, disease-risk measure or another defined endpoint.
• Mechanistic plausibility is not equivalent to demonstrated human benefit. Mechanism ≠ clinical outcome.
• Evidence transfer must consider the stage of translation: Cell → Animal → Human Physiology → Human Clinical Outcome. Evidence from an earlier stage must not be presented as proof of a later stage without sufficient human evidence.
• Animal models may provide mechanistic or preclinical information but do not automatically establish extended human lifespan or improved human healthspan.
• Evidence of lifespan extension in cells, model organisms or animals is not evidence of human lifespan extension.
• Observational data may provide relevant associations but do not automatically establish causation or the effect of an intervention.
• Relative Risk, Absolute Risk and individual prognosis are distinct concepts. A population-level risk reduction must not automatically be communicated as an individual guarantee.
• Population-level mortality associations do not automatically support individual lifespan prediction.
• Healthy-ageing communication should consider preservation of function, health and quality of life and should not be reduced solely to maximal lifespan or individual biomarkers.
• Healthspan refers to years lived with preserved health and function, but it is not a single universal metric. Specific claims must state how healthspan is operationalized through defined outcomes or criteria.
• Healthy ageing and healthspan must not be reduced solely to the absence of diagnosed disease where the specific claim also concerns function, resilience or quality of life.
• Lifestyle interventions involving nutrition, exercise, sleep and stress must be interpreted in accordance with H-05, H-07, H-06 and H-09; their general health relevance does not automatically establish a specific life-extension claim.
• Supplements and nutritional interventions marketed for longevity must comply with H-04. An ingredient must not be presented as extending human lifespan solely on the basis of mechanistic, animal or biomarker evidence.
• Hormone-related longevity or anti-ageing interventions must consider H-10. Moving a hormone value toward a preferred range does not establish longevity benefit.
• Wearables, consumer devices and algorithmic longevity or recovery scores must comply with H-03. Displayed precision is not automatically clinical accuracy.
• Heat, cold, light, altitude or other environmental longevity claims must comply with H-08. Short-term physiological responses do not establish long-term longevity outcomes.
• New, experimental or insufficiently validated longevity interventions must comply with H-12. Experimental does not mean ineffective. It means not yet sufficiently established.
• Professionals must consider benefit, uncertainty, burden, opportunity cost and relevant risk together when evaluating a longevity intervention. Opportunity cost may include money, time, attention, burden or displacement of better-supported actions. A theoretical long-term benefit does not automatically justify meaningful current risk.
• Combinations must be assessed together. Assess the stack, not only the parts. Multiple supplements, medications, fasting, exercise, heat, cold, hormones or experimental interventions may create a different cumulative risk profile.
• Prevention, screening or early-detection activities must not be recommended or interpreted outside applicable guidelines, scope or clinical requirements solely because they are labeled “longevity.” More screening is not automatically better screening. False positives, incidental findings, unnecessary downstream testing, overdiagnosis, burden and opportunity cost should be considered where relevant.
• Professionals must not infer an individual's lifespan, “years added,” time of death or guaranteed healthspan extension from biomarkers, scores, family history or lifestyle data unless such a statement is supported by an appropriately validated method and professional scope.
• Anti-ageing or longevity marketing must not unnecessarily pathologize normal ageing or rely on unsupported urgency or fear-based claims.
• Ageing is a biological process, not by itself a diagnosis. Age-associated diseases may be medically relevant, but normal ageing must not be marketed broadly as though it were itself a disease.
• Monitoring of a longevity intervention must match the actual goal and risk. An improved marker must not lead Professionals to ignore relevant symptoms, functional deterioration or adverse effects.
• Where new symptoms, relevant adverse responses or questions requiring medical diagnosis, medication management or other clinical assessment arise, scope awareness and appropriate referral apply.
• Where possible acute danger is present, IHPSO Referral Levels and local emergency procedures apply. H-11 does not constitute medical triage.
• Where an IHPSO Evidence Classification is used, it must apply to a specific Longevity, Lifespan, Healthspan, Biological-Age, Biomarker or Outcome claim and must not be assigned broadly to an entire intervention.